Condition

AML (Acute Myeloid Leukemia) clinical trials and research

• 17Clinical trials
• 2New in 30 days
• 6Countries

Newest AML (Acute Myeloid Leukemia) clinical trials

All recruiting trials (17)

• Interferon-α Maintenance for Favorable-Risk AML

  This study tests pegylated interferon alfa-2b as maintenance therapy to see if it helps keep favorable-risk AML in remission after initial treatment.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07925554

• CARCIK-CD123/33 cells for relapsed or refractory AML and BPDCN in children and adults

  This trial tests CARCIK-CD123/33 cell therapy to see if it is safe and feasible for people with relapsed or refractory AML or BPDCN, including kids and adults, before planned stem cell transplant.

  Recruiting Phase 1/2 Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Monza, MB and 1 other locations · NCT07877610

• Soursop tea in relapsed/refractory AML or multiple myeloma

  This pilot study tests whether drinking tea made from soursop leaves can help reduce cancer cells in people with relapsed or refractory AML or MM.

  Recruiting Early Phase 1 Cooper Norcross Health · Camden, New Jersey · NCT07771803

• CHM-029 in adults with certain AML mutations or rearrangements

  This study tests whether an oral medicine called CHM-029 is safe and shows signs of activity in adults with relapsed or treatment-resistant AML with specific genetic features.

  Recruiting at 8 sites Phase 1 Charm Therapeutics · Duarte, California and 7 other locations · NCT07751991

• Venetoclax with Decitabine vs Venetoclax with DA vs standard DA in newly diagnosed AML

  This trial tests three induction regimens in adults with newly diagnosed AML to see which combination best balances effectiveness and tolerability.

  Recruiting Phase 3 The Second Affiliated Hospital of Kunming Medical University · Kunming, Yunnan · NCT07712848

• Ivosidenib as maintenance therapy for IDH1-mutated AML or high-risk MDS in patients ineligible for transplant

  This study tests whether continuing ivosidenib after induction helps people with IDH1-mutated AML or high-risk MDS who can’t have a transplant, to see if it helps keep cancer from returning.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07607418

• Haplo-cord Blood Transplant for AML and high-risk MDS

  This study tests a haploidentical-cord blood stem cell transplant approach in patients with AML or high-risk MDS to see how different engraftment patterns affect outcomes.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian and 3 other locations · NCT07588360

• VA-CIG as initial intensive therapy for fit adults with acute myeloid leukemia

  This study will test whether combining venetoclax with azacitidine, idarubicin, low-dose cytarabine, and G-CSF works as induction treatment for adults aged 18–70 with previously untreated, fit AML.

  Recruiting Phase 2 Beijing 302 Hospital · Beijing · NCT07514832

• Wearable monitoring to collect health data in people receiving transfusions for blood cancers

  This project will try a wrist-worn accelerometer to see if continuous activity and symptom tracking helps doctors understand and support adults with MDS, AML or related blood cancers who need transfusions.

  Recruiting University of Oxford · Oxford, OXFORDSHIRE · NCT07511829

• Olutasidenib drug interaction testing for IDH1‑mutant cancers

  This trial tests whether the cancer drug olutasidenib changes how the body processes other medicines in adults with IDH1‑mutation positive cancers.

  Recruiting at 2 sites Phase 4 Rigel Pharmaceuticals · Orange, California and 1 other locations · NCT07486713

• CD64 CAR T Therapy for Adults with Relapsed or Refractory AML

  This phase 1 study tests a patient’s own CD64-directed CAR T cells to see if they can be safely given and potentially help adults with relapsed or refractory AML.

  Recruiting Phase 1 University of Colorado, Denver · Aurora, Colorado · NCT07347418

• Chidamide maintenance after stem cell transplant for intermediate- or high-risk AML

  This trial tests whether taking oral chidamide after an allogeneic stem cell transplant helps adults with intermediate- or high-risk AML stay in remission and live longer.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Shijiazhuang, Hebei and 4 other locations · NCT07304232

• Treosulfan vs Melphalan conditioning before allogeneic transplant in AML/MDS

  In this study, adults with AML or MDS who are getting an allogeneic transplant try two different conditioning regimens (Treosulfan or Melphalan) to see which one works better and is easier to tolerate.

  Recruiting at 16 sites Phase 2 Technische Universität Dresden · Aachen and 16 other locations · NCT07025824

• CBX-250 for relapsed or refractory myeloid leukemias.

  This will try CBX-250, a new injectable medicine, in people aged 12 and older with relapsed or refractory AML, high-risk MDS, CMML, or CML to see if it can control disease with tolerable side effects.

  Recruiting at 11 sites Phase 1 Crossbow Therapeutics, Inc. · Duarte, California and 10 other locations · NCT06994676

• Using patient-derived mouse models to find drugs that make venetoclax plus azacitidine work better in AML

  This project will test whether adding sensitizing drugs to venetoclax and azacitidine helps kill leukemia cells in people with AML by using patient-derived mouse models.

  Recruiting at 3 sites Clinical Hub for Interventional Research (CHOIR) · Canberra, Australian Capital Territory and 3 other locations · NCT06782971

• Combining Gilteritinib with Venetoclax and Azacitidine for AML Patients with FLT3 Mutations

  This study is testing if adding Gilteritinib to the standard treatments of Venetoclax and Azacitidine can help newly diagnosed AML patients with FLT3 mutations who can't have intensive chemotherapy.

  Recruiting Phase 2 Technische Universität Dresden · Dresden · NCT06696183

• CD123-targeted CAR-NK therapy for relapsed/refractory AML or BPDCN

  This study is testing a new treatment using special immune cells to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Wuhan, Hubei · NCT06690827

Related topics

Quick answers

How many AML (Acute Myeloid Leukemia) clinical trials are recruiting right now?

17, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 6 countries. The most sites are in China (7 trials), United States (5 trials), United Kingdom (2 trials), Germany (2 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 1: 4, Phase 3: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →